• Product name
    Anti-Integrin alpha V antibody [P2W7]
    See all Integrin alpha V primary antibodies
  • Description
    Mouse monoclonal [P2W7] to Integrin alpha V
  • Host species
  • Tested applications
    Suitable for: IP, ICC/IF, WB, Flow Cytmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    An ocular melanoma cell line expressing high levels of human integrin alpha V beta 1.

  • Positive control
    • Tested with squamous cell carcinoma cells. A375M melanoma cell line. A549 cell line IF/ICC
  • General notes
    Human alpha v is about 150-160kDa under non-reducing conditions. Under reducing conditions it is cleaved into 2 bands of about 125-130kDa +20-25kDa.



Our Abpromise guarantee covers the use of ab11470 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IP Use at an assay dependent concentration.
ICC/IF Use at an assay dependent concentration.
WB Use at an assay dependent concentration.
Flow Cyt Use a concentration of 1 - 10 µg/ml.

ab170190 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.



  • Function
    The alpha-V integrins are receptors for vitronectin, cytotactin, fibronectin, fibrinogen, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin and vWF. They recognize the sequence R-G-D in a wide array of ligands. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.
  • Sequence similarities
    Belongs to the integrin alpha chain family.
    Contains 7 FG-GAP repeats.
  • Cellular localization
  • Information by UniProt
  • Database links
  • Alternative names
    • antigen identified by monoclonal antibody L230 antibody
    • CD 51 antibody
    • CD51 antibody
    • DKFZp686A08142 antibody
    • Integrin alpha five antibody
    • integrin alpha V beta 3 antibody
    • Integrin alpha-5 antibody
    • integrin alpha-V antibody
    • Integrin alpha-V light chain antibody
    • integrin alphaVbeta3 antibody
    • integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51) antibody
    • ITAV_HUMAN antibody
    • ITGAV antibody
    • MSK 8 antibody
    • Msk8 antibody
    • Vitronectin receptor subunit alpha antibody
    • VNRA antibody
    • VTNR antibody
    see all


  • ICC/IF image of ab11470 stained A549 cells. The cells were 4% formaldehyde fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab11470, 5µg/ml) overnight at +4°C. The secondary antibody (green) was ab96879, a goat anti-mouse DyLight® 488 (IgG; H+L) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.

  • Overlay histogram showing A549 cells stained with ab11470 (red line). The cells were fixed with 80% methanol (5 min) and incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab11470, 1µg/1x106 cells) for 30 min at 22ºC. The secondary antibody used was a goat anti-mouse DyLight® 488 (IgG; H+L) (ab96879) at 1/500 dilution for 30 min at 22ºC. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 2µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed. This antibody gave a positive result in 4% paraformaldehyde (10 min) fixed A549 cells used under the same conditions.

    Please note that Abcam do not have any data for use of this antibody on non-fixed cells. We welcome any customer feedback.


This product has been referenced in:
  • Megiorni F  et al. Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells. J Hematol Oncol 10:161 (2017). WB ; Human . Read more (PubMed: 28985758) »
  • Farsinejad A  et al. Classification of Iranian patients with Glanzmann's Thrombasthenia using a flow cytometric method. Platelets 22:321-7 (2011). Read more (PubMed: 21526886) »

See all 4 Publications for this product

Customer reviews and Q&As

Thank you for contacting us. I am very sorry for the delay in getting back to you, I have been trying to collect additional information about this clone to share with you in order to clarify the situation.

It appears that we have made a mist...

Read More


Sign up